Search
YS-ON-001
go.drugbank.com/drugs/DB17291InvestigationalYS-ON-001 is a combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium).
Tavokinogene telseplasmid
go.drugbank.com/drugs/DB17301InvestigationalTavokinogene telseplasmid consists of a DNA Plasmid Vector Encoding IL-12.
Synonyms: Dna plasmid containing genes coding for the human interleukin 12 (il-12) p35 and p40 subunits that are separated by an internal ribosomal entry site (ires) and under the control of a single cytomegalovirusSNS01-T
go.drugbank.com/drugs/DB17302InvestigationalSNS01-T is a gene therapy nanoparticle. … It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.
Maveropepimut-S
go.drugbank.com/drugs/DB17339InvestigationalMaveropepimut-S is a T cell activating immunotherapy.
ENB-003
go.drugbank.com/drugs/DB17340InvestigationalENB-003 is a selective and potent inhibitor of the endothelin B receptor (ETBR) being investigated for cancer.
MORAb-066
go.drugbank.com/drugs/DB17347InvestigationalMORAb-066 is a humanized antibody directed against tissue factor (TF). It is being investigated in pancreatic cancer.
AMG 424
go.drugbank.com/drugs/DB17357InvestigationalAMG 424 is a novel, humanized, anti-CD3/CD38 bispecific monoclonal antibody being investigated for multiple myeloma.
MB-102 CD123 CAR
go.drugbank.com/drugs/DB17366InvestigationalMB-102 are autologous T cells genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor.
Gavocabtagene autoleucel
go.drugbank.com/drugs/DB17367InvestigationalGavocabtagene autoleucel is a novel cell therapy consisting of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit
DCLL-9718S
go.drugbank.com/drugs/DB17392InvestigationalDCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine